Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Current Liabilities (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Total Current Liabilities for 10 consecutive years, with $5.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 1.5% to $5.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.7 million, a 1.5% increase, with the full-year FY2024 number at $5.7 million, up 31.11% from a year prior.
  • Total Current Liabilities was $5.7 million for Q3 2025 at Rein Therapeutics, down from $7.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $7.7 million in Q2 2025 to a low of $1.2 million in Q2 2023.
  • A 5-year average of $4.4 million and a median of $4.5 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: plummeted 76.76% in 2023, then soared 312.45% in 2024.
  • Rein Therapeutics' Total Current Liabilities stood at $4.5 million in 2021, then decreased by 24.93% to $3.4 million in 2022, then grew by 29.58% to $4.4 million in 2023, then soared by 31.11% to $5.7 million in 2024, then fell by 0.09% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Total Current Liabilities are $5.7 million (Q3 2025), $7.7 million (Q2 2025), and $6.0 million (Q1 2025).